# Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)

> **NCT03797040** · PHASE1 · UNKNOWN · sponsor: **Pluristem Ltd.** · enrollment: 27 (estimated)

## Conditions studied

- Ionizing Radiation Exposure

## Interventions

- **BIOLOGICAL:** Cell therapy

## Key facts

- **NCT ID:** NCT03797040
- **Lead sponsor:** Pluristem Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797040, "Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03797040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*